Linda Louise Glowacki

Dr. Linda Louise Glowacki

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
LBLana Brockbals
Lana Brockbals
YWYannick Wartmann
Yannick Wartmann
DMDylan Mantinieks
Dylan Mantinieks
LGLinda Louise Glowacki
Linda Louise Glowacki
DGDimitri Gerostamoulos
Dimitri Gerostamoulos
Andrea Eva SteuerAndrea Eva Steuer
Andrea Eva Steuer
Postmortem redistribution (PMR) can result in artificial drug concentration changes following death and complicate forensic case interpretation. Currently, no accurate methods for PMR prediction exist. Hence, alternative strategies were developed investigating the time-dependent postmortem behavior of diazepam, nordiazepam, morphine, codeine, mirtazapine and citalopram. For 477 authentic postmortem cases, femoral blood samples were collected at two postmortem time-points. All samples were quantified for drugs of abuse (targeted; liquid chromatography-tandem mass spectrometry LC-MS/MS) and characterized for small endogenous molecules (untargeted; gas chromatography-high resolution MS (GC-HRMS). Trends for significant time-dependent concentration decreases (diazepam (n = 137), nordiazepam (n = 126)), increases (mirtazapine (n = 55), citalopram (n = 50)) or minimal median postmortem changes (morphine (n = 122), codeine (n = 92)) could be observed. Robust mathematical mixed effect models were created for the generalized postmortem behavior of diazepam and nordiazepam, which could be used to back-calculate drug concentrations towards a time-point closer to the estimated time of death (caution: inter-individual variability). Significant correlations between time-dependent concentration changes of morphine, mirtazapine and citalopram with individual endogenous molecules could be determined; no correlation was deemed strong enough for successful a posteriori estimation on the occurrence of PMR for specific cases. The current dataset did successfully lead to a significant knowledge gain in further understanding the time-dependent postmortem behavior of the studied drugs (of abuse).

27 August 2024 in Journal of Analytical Toxicology
Verified
Journal Article
Closed access
PDF file
ODOlaf H Drummer
Olaf H Drummer
SJSamantha Joubert
Samantha Joubert
MRMatthew Di Rago
Matthew Di Rago
JCJared Castle
Jared Castle
KCKerryn Crump
Kerryn Crump
DGDimitri Gerostamoulos
Dimitri Gerostamoulos
Novel benzodiazepine (NBz) detections in Victorian coronial cases started early in 2018 and have continued to increase in number and type up to December 2022. The 11 different NBz detections included etizolam (n = 82), flualprazolam (n = 43), clonazolam or 8-aminoclonazolam (n = 30), bromazolam (n = 15), clobromazolam (n = 13), phenazepam (n = 13), flubromazolam (n = 12), flubromazepam (n = 8), desalkylflurazepam (n = 6), diclazepam (n = 2), and estazolam (n = 1). The pattern of detections varied over the 5-year period, with different compounds appearing over different time frames. The most recent NBz to appear were bromazolam, clobromazolam, flubromazepam, and phenazepam, whereas etizolam had been seen regularly in case work since 2018. Of the total 133 deaths, 95 were considered drug-related deaths by forensic pathologists with at least one additional CNS depressant also present capable of contributing to death. All deaths involved other (non-benzodiazepine) CNS active drugs, although many involved multiple NBz, with five or more different benzodiazepines detected in eight cases.

17 August 2022 in Journal of Analytical Toxicology
Verified
Journal Article
Closed access
PDF file
DGDimitri Gerostamoulos
Dimitri Gerostamoulos
LGLinda Louise Glowacki
Linda Louise Glowacki
MPMaria Pricone
Maria Pricone
KCKerryn Crump
Kerryn Crump
MRMatthew Di Rago
Matthew Di Rago
ODOlaf H Drummer
Olaf H Drummer
Six fatalities have occurred from the ingestion of a combination of new psychoactive substances (NPSs), 4-fluoroamphetamine (4FA) and 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25C-NBOMe) over a 9-month period. Four of these fatalities (one older female and three young males) were from direct adverse effects of drugs, and one each from a fall while being intoxicated and during restraint. All cases were subject to full postmortem examinations that included collection of femoral blood. The four drug-caused fatalities had postmortem blood concentrations for 4FA and 25C-NBOMe of 330–682 ng/L (median 417) and 1.4–12 ng/mL (median 4.3), respectively. The other two cases (both young males) where death was considered to have been caused indirectly by drug intoxication had 4FA and 25C-NBOMe postmortem concentrations of 21 and 123 ng/mL, and 1.8 and 4.5 ng/mL, respectively. None of these cases showed concentrations of drugs that suggested use of high recreational doses. In one drug-caused death, capsules and a brown powder obtained from the scene were found to contain a mixture of these two NPSs. With the exception of one drug-caused death, other drugs were detected; however, the effects of the two NPSs together were regarded as the primary triggers for the deaths. There were no consistent symptoms or pathology in these cases; however, agitation/aggression was observed in two cases prior to their collapse, with seizures in possibly three cases. Pulmonary and/or cerebral edema was noted in three cases. Potentially significant natural disease (a mildly enlarged heart) was only observed in one drug-caused case. These cases illustrate a possible increased risk of sudden death with this combination of drugs, both of which can elevate serotonin concentrations as well as act as strong stimulants. These cases also illustrate the difficulty in detecting NPS in cases where no prior information is available that might suggest their use.

30 December 2023 in Drug Testing and Analysis
Verified
Journal Article
Open access
DMDylan Mantinieks
Dylan Mantinieks
MRMatthew Di Rago
Matthew Di Rago
ODOlaf H. Drummer
Olaf H. Drummer
LGLinda Louise Glowacki
Linda Louise Glowacki
JSJennifer Schumann
Jennifer Schumann
DGDimitri Gerostamoulos
Dimitri Gerostamoulos
A multi‐analyte liquid chromatography‐tandem mass spectrometry (LC‐MS/MS) method is described, involving the separation of delta‐9‐tetrahydrocannabinol (delta‐9‐THC) and delta‐8‐THC in addition to other commonly encountered drugs and metabolites. Briefly, sample preparation involved an alkaline liquid–liquid extraction (methyl tert‐butyl ether) of blood (100 μl). The solvent layer was transferred, evaporated to dryness, reconstituted, and samples then separated on an Agilent Poroshell 120 EC‐C18 100 Å (50 mm × 3.0 mm, 2.7 μm) analytical column using a multi‐step gradient elution of 50 mM ammonium formate in water (pH 3.5) and 0.1% formic acid in methanol over 14 min. A SCIEX Triple Quad 6500+ system operating in scheduled multiple reaction monitoring and positive electrospray ionization was used for detection. There were no interferences, and matrix effects were generally acceptable (±20% of neat response). Linearity was achieved within the calibration range, including methylamphetamine (MA) (10–1000 ng/ml), 3,4‐methylenedioxy‐N‐methylamphetamine (MDMA) (10–1,000 ng/ml), cocaine (10–1000 ng/ml), and two THC isomers (1–100 ng/ml). Accuracies of MA, MDMA, cocaine, and two THC isomers were 3.6 to 8.9%, −1.2 to 4%, −5.3 to 5.8%, and −11 to 14%, respectively; while precision estimates of the same were 1.6 to 5.4%, 1.7 to 5.3%, 1.2 to 4.5%, and 2 to 10%, respectively. Autosampler stability and dilution integrity were within acceptable limits, and no carryover was detected at the limit of detection. This validated LC‐MS/MS method made the routine identification of both delta‐9‐THC and delta‐8‐THC in blood possible.

23 February 2024 in Journal of Analytical Toxicology
Verified
Journal Article
Closed access
PDF file
JCJared Castle
Jared Castle
RSRebekka Syrjanen
Rebekka Syrjanen
MRMatthew Di Rago
Matthew Di Rago
JSJennifer Schumann
Jennifer Schumann
SGShaun L Greene
Shaun L Greene
DGDimitri Gerostamoulos
Dimitri Gerostamoulos
The proliferation of novel psychoactive substances (NPSs) continues to challenge toxicology laboratories. In particular, the United Nations Office on Drugs and Crime considers designer benzodiazepines to be a current primary threat among all NPSs. Herein, we report detection of a new emerging designer benzodiazepine, clobromazolam, using high-resolution mass spectrometry and untargeted data acquisition in combination with a “suspect screening” method built from the crowd-sourced HighResNPS.com database. Our laboratory first detected clobromazolam in emergency department presenting intoxications included within the Emerging Drugs Network of Australia—Victoria project in the state of Victoria, Australia, from April 2022 to March 2023. Clobromazolam was the most frequent designer benzodiazepine detected in this cohort (100/993 cases, 10%). No patients reported intentional administration of clobromazolam, although over half reported exposure to alprazolam, which was detected in only 7% of cases. Polydrug use was prevalent (98%), with phenazepam (45%), methylamphetamine (71%) and other benzodiazepines (60%) most frequently co-detected. This is the first case series published in the literature concerning clobromazolam in clinical patients. The identification of clobromazolam in patients presenting to emergency departments in Victoria demonstrates how high-resolution mass spectrometry coupled with the HighResNPS.com database can be a valuable tool to assist toxicology laboratories in keeping abreast of emerging psychoactive drug use.

26 October 2026 in Accident Analysis & Prevention
Verified
Journal Article
Closed access
ODOlaf H. Drummer
Olaf H. Drummer
MRMatthew Di Rago
Matthew Di Rago
CMCarla Morris
Carla Morris
GWGemma Wynd
Gemma Wynd
LGLinda Louise Glowacki
Linda Louise Glowacki
DGDimitri Gerostamoulos
Dimitri Gerostamoulos